SCHEMBL2834769

SCHEMBL2834769

Cc1ccc(C(NC(=O)OC(C)(C)C)C(O)c2ccc(I)cc2)cc1F

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
POLB P06746 2/20 0.39
TP53 P04637 1/20 0.38
LMNA P02545 5/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
HTT P42858 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
AAK1 Q2M2I8 1/20 0.36
TRPA1 O75762 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRB2 P47870 1/20 0.35
S1PR3 Q99500 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837541 0.88 S1PR3 (0.38) ALDH1A1LMNAHTTNPSR1AAK1
SCHEMBL2837593 0.87 PDE2A (0.40) AAK1
SCHEMBL2833402 0.86 MEN1 (0.36) ALDH1A1TP53LMNAKMT2AMEN1
SCHEMBL2832183 0.84 S1PR3 (0.35) ALDH1A1KMT2AMEN1HTTAAK1
SCHEMBL2833981 0.82 CYP3A4 (0.40) ALDH1A1POLBTP53LMNAKMT2A
SCHEMBL2834220 0.81 S1PR3 (0.42) ALDH1A1LMNAHTTSMN1; SMN2AAK1
SCHEMBL2832212 0.81 TRPA1 (0.41) ALDH1A1POLBTP53LMNAKMT2A
SCHEMBL2833210 0.81 AKR1C3 (0.41) AAK1S1PR3AKR1C3AKR1C2
SCHEMBL2834488 0.80 PPARG (0.42) GABRB1GABRB2
SCHEMBL2833280 0.79 S1PR3 (0.42) ALDH1A1TP53SMN1; SMN2AAK1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 ALDH1A1 209/4885POLB 2783/4885TP53 2446/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 ALDH1A1 209/4885POLB 2783/4885TP53 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.